Page 136 - Human Use News Today

Investegate announcements from ObsEva SA, ObsEva Announces European Commission Marketing Authorization for Yselty® (linzagolix), an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids

17.06.2022 - -Yselty (linzagolix) is the first and only approved GnRH antagonist to provide flexible dosing options with and without hormonal add-back therapy- -Theramex to commercialize Yselty; ObsEva to receive royalties on commercial sales, as well as ... Seite 1

AstraZeneca’s Covid-19 vaccine, ChAdOx1-S, has been granted approval in the European Union (EU) by the European Medicine Agency (EMA) as a third dose

These are the International Medical Device Regulatory Forum, the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use and the Medical Devices Innovation Consortium.

The global regulatory affairs outsourcing market was valued at $8.2 billion in 2021 and is expected to reach $16.8 billion by 2027. ...

After decades of development and a trail of failed clinical trials, gene therapy is finally emerging as a worthwhile approach for treating a range of acquired and inherited diseases

(RTTNews) - The FDA has approved Eli Lilly and Co. (LLY) and Incyte Corp.s (INCY) Olumiant for yet another indication, this time, for the treatme...

(RTTNews) - The U.S. Food and Drug Administration approved Eli Lilly and Co.s Olumiant (baricitinib) oral tablets to treat adult patients with se...

/PRNewswire/ -- AMIVAS Ireland Ltd., specialists in treatments for rare and neglected tropical diseases, including severe malaria, announced today the...

Baricitinib, a JAK inhibitor, is now approved for the treatment of adults with severe AA. The disease affects more than 300,000 people in the US every year.